PSMA PET/CT with Glu-urea-Lys-(Ahx)-(68Ga(HBED-CC)) versus 3D CT volumetric lymph node assessment in recurrent prostate cancer

• Verfasst von: Giesel, Frederik L. [VerfasserIn]
• Verfasst von: Sterzing, Florian [VerfasserIn]
• Verfasst von: Rius, Maria [VerfasserIn]
• Verfasst von: Kopka, Klaus [VerfasserIn]
• Verfasst von: Afshar-Oromieh, Ali [VerfasserIn]
• Verfasst von: Haberkorn, Uwe [VerfasserIn]
• Verfasst von: Kratochwil, Clemens [VerfasserIn]
• Titel: PSMA PET/CT with Glu-urea-Lys-(Ahx)-(68Ga(HBED-CC)) versus 3D CT volumetric lymph node assessment in recurrent prostate cancer
• Verf.angabe: Frederik L. Giesel, H. Fiedler, M. Stefanova, F. Sterzing, M. Rius, K. Kopka, J.H. Moltz, A. Afshar-Oromieh, P.L. Choyke, U. Haberkorn, C. Kratochwil
• E-Jahr: 2015
• Jahr: 11 July 2015
• Umfang: 7 S.
• Teil: volume:42
• Teil: year:2015
• Teil: number:12
• Teil: pages:1794-1800
• Teil: extent:7
• Fussnoten: Im Titel ist der Ausdruck "68Ga(HBED-CC)" eckig geklammert ; Im Titel ist die Zahl 68 hochgestellt ; Gesehen am 10.08.2021
• Titel Quelle: Enthalten in: European journal of nuclear medicine and molecular imaging
• Ort Quelle: Heidelberg [u.a.] : Springer-Verl., 2002
• Jahr Quelle: 2015
• Band/Heft Quelle: 42(2015), 12, Seite 1794-1800
• ISSN Quelle: 1619-7089
• DOI: doi:10.1007/s00259-015-3106-6
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1766021190

Abstract

Purpose: PET/CT with the PSMA ligand is a powerful new method for the early detection of nodal metastases in patients with biochemical relapse. The purpose of this retrospective investigation was to evaluate the volume ad dimensions of nodes identified by Glu-urea-Lys-(Ahx)-[68Ga(HBED-CC)] (68Ga-PSMA-11) in the setting of recurrent prostate cancer. Methods: All PET/CT images were acquired 60 ± 10 min after intravenous injection of 68Ga-PSMA-11 (mean dose 176 MBq). In 21 patients with recurrent prostate cancer and rising PSA, 49 PSMA-positive lymph nodes were identified. Using semiautomated lymph node segmentation software, node volume and short-axis and long-axis dimensions were measured and compared with the maximum standardized uptake values (SUVmax). Round nodes greater than or equal to 8 mm were considered positive by morphological criteria alone. The percentage of nodes identified by elevated SUVmax but not by conventional morphological criteria was determined. Results: The mean volume of 68Ga-PSMA-11-positive nodes was 0.5 ml (range 0.2 – 2.3 ml), and the mean short-axis diameter was 5.8 mm (range 2.4 – 13.3 mm). In 7 patients (33.3 %) with 31 PSMA-positive nodes only 11 (36 %) were morphologically positive based on diameters >8 mm on CT. In the remaining 14 patients (66.7 %), 18 (37 %) of PSMA positive lymph nodes had short-axis diameters <8 mm with a mean short-axis diameter of 5.0 mm (range 2.4 – 7.9 mm). Thus, in this population, 68Ga-PSMA-11 PET/CT detected nodal recurrence in two-thirds of patients who would have been missed using conventional morphological criteria. Conclusion: 68Ga-PSMA-11 PET/CT is more sensitive than CT based 3D volumetric lymph node evaluation in determining the node status of patients with recurrent prostate cancer, and is a promising method of restaging prostate cancers in this setting.